Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase

Amit Goyal, Robert G Newcombe, Alok Chhabra, Robert E Mansel, ALMANAC Trialists Group, Mike Dixon

Research output: Contribution to journalArticlepeer-review

Abstract

Despite the widespread application of sentinel lymph node biopsy (SLNB) for early stage breast cancer, there is a wide variation in reported test performance characteristics. A major aim of this prospective multicentre validation study was to quantify detection and false-negative rates of SLNB and evaluate factors influencing them.
Original languageEnglish
Pages (from-to)203-8
Number of pages6
JournalBreast cancer research and treatment
Volume99
Issue number2
DOIs
Publication statusPublished - Sep 2006

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Axilla
  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Carcinoma, Lobular
  • False Negative Reactions
  • Female
  • Humans
  • Lymph Nodes
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Predictive Value of Tests
  • Prospective Studies
  • Radiopharmaceuticals
  • Risk Factors
  • Rosaniline Dyes
  • Sentinel Lymph Node Biopsy
  • Technetium Tc 99m Aggregated Albumin

Fingerprint

Dive into the research topics of 'Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase'. Together they form a unique fingerprint.

Cite this